News & Insights
By Dr. Philip R. O. Payne, PhD, FACMI, Co-founder Signet Accel There have been a variety of publications and debates over the past several years arguing for the adoption of lessons learned from the private sector in order to increase the speed, scale, and scope of innovation in the healthcare and life sciences research communities. At their core, these arguments speak to the need to increase the agility and data-centricity of investigative efforts that seek to develop and disseminate new biomedical knowledge. However, when considering such a charge, a number of important questions come to mind, specifically: 1) can we map the role of a researcher to that of an entrepreneur, as one would find in the private sector; and 2) what are the foundational resources needed for such researchers to pursue their activities in a manner that is analogous to entrepreneurs in the private sector?
The biopharmaceutical industry is under tremendous pressure to deliver more robust research methodologies, investigate new treatments, and better understand (and predict) interactive affects for those with comorbidities and concomitant treatments. Yet, at the same time, an estimated 80% of healthcare data remains unstructured, and therefore locked and inaccessible.